NOVARTIS AG great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com. Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library For questions about the site or required registration, please contact media.relations@novartis.com References 1. Barratt J, Rovin B, Zhang H, et al. Interim analysis of a Phase 2 dose ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy. Presented at the ERA-EDTA congress. 2. Thompson A, Carroll K, Inker LA, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469--481. 3. McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414--430. 4. Nam KH, Kie JH, Lee MJ, et al. Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One. 2014;9(7):e101935. 5. Abbasi MA, Chertow GM, Hall YN. End-stage renal disease. BMJ Clin Evid. 2010;2010. 6. Bulut IK, Mir S, Sozeri B, et al. Outcome results in children with IgA nephropathy: a single center experience. Int J Nephrol Renovasc Dis. 2012;5:23--28. 7. Selvaskandan H, Cheung CK, Muto M, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23(5):577--588. 8. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. 2015;4(1):57--73. 9. Wong E, Praga M, Nester C, et al. Iptacopan (LNP023): a novel oral complement alternative pathway factor B inhibitor safely and effectively stabilises eGFR in C3 glomerulopathy. To be presented at the ERA-EDTA congress. 10. Novartis. Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN). Available at: https://www.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan. Accessed April 2021. 11. Novartis. Data on file. 12. Novartis. Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G. Available at: https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g. Accessed April 2021. 13. Novartis. Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G). Available at: https://www.novartis.com/news/media-releases/novartis-received-europe an-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy -c3g. Accessed April 2021. 14. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I -- molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262. 15. Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926--7931. 16. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227--235. 17. Willows J, Brown M, Sheerin NS. The role of complement in kidney disease. Clin Med. 2020;20(2):156--160. 18. ukawska E, Polcyn-Adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med. 2018;18(3):297--318. 19. Koscielska-Kasprzak K, Bartoszek D, Myszka M, Zabinska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz). 2014;62(1):47--57. 20. De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney disease caused by dysregulation of the complement alternative pathway: An etiologic approach. J Am Soc Nephrol. 2015;26(12):2917--2929. 21. Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177--3183. 22. Sevillano AM, Gutiérrez E, Yuste C, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089--3099. 23. Xie J, Kiryluk K, Wang W, et al. Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score. PLoS One. 2012;7(6):e38904. 24. Ramamoorthy S, Cidlowski JA. Corticosteroids-Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016;42:15--31. 25. Coppo R. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol. 2017;28:25--33. 26. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677--686. # # # Novartis Media Relations E-mail: media.relations@novartis.com Jamie Bennett Phil McNamara Novartis US External Communications Novartis Cardio-Renal- Metabolic +1 862 778 3503 Communications jamie.bennett@novartis.com +1 862 778 0218 (direct) +1 862 274 5255 (mobile) Julie Masow philip.mcnamara@novartis.com Novartis US External Communications +1 862 579 8456 (mobile) julie.masow@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com Central North America Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052 Thomas Hungerbuehler +41 61 324 8425 Isabella Zinck +41 61 324 7188
(END) Dow Jones Newswires
June 06, 2021 06:06 ET (10:06 GMT)
